Showing results (111-120 of 232) with videos related to
Sort By:
Pageof 24
Inflammatory Bowel Diseases|July 9, 2011
Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levelsFrancis Vasseur, Boualem Sendid, Thierry Jouault, et al.Gastroenterology|August 12, 2009
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's diseaseKonstantinos Karmiris, Gilles Paintaud, Maja Noman, et al.Clinical Chemistry|January 26, 2008
Anti-alpha-enolase antibodies in patients with inflammatory Bowel diseaseNathalie Vermeulen, Ingrid Arijs, Sofie Joossens, et al.Inflammatory Bowel Diseases|November 7, 2022
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical ProgramGary R Lichtenstein, Brian Bressler, Carlos Francisconi, et al.Ebiomedicine|January 6, 2020
Mucosal microbial load in Crohn's disease: A potential predictor of response to faecal microbiota transplantationGuillaume Sarrabayrouse, Stefania Landolfi, Marta Pozuelo, et al.Journal of Crohn'S & Colitis|March 30, 2016
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to InfliximabKonstantinos Papamichael, Oliviane Rivals-Lerebours, Thomas Billiet, et al.European Journal of Gastroenterology & Hepatology|July 11, 2006
NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationshipSilvija Cukovic-Cavka, Severine Vermeire, Irena Hrstic, et al.Journal of Crohn'S & Colitis|January 13, 2021
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyWilliam J Sandborn, Brian G Feagan, Stephen Hanauer, et al.Gut|February 10, 2017
A microbial signature for Crohn's diseaseVictoria Pascal, Marta Pozuelo, Natalia Borruel, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2019
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug DevelopmentWalter Reinisch, Klaus Gottlieb, Jean-Frederic Colombel, et al.Pageof 24